Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin in Acute Basilar Artery Occlusion
NCT06489925Phase 1Not yet recruiting
- Sponsor
- University Hospital Center Sestre milosrdnice
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Native Peptides
01
Overview
Phase 1, open-label, single-arm trial of cerebrolysin in Posterior Circulation Stroke (PCS) and basilar artery occlusion (BAO), sponsored by University Hospital Center Sestre milosrdnice. Primary endpoints: Modified Rankin Scale Score 0-3 at 90 days and Mortality Rate at 90 days. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
cerebrolysin
03
Conditions
Posterior Circulation Stroke (PCS)basilar artery occlusion (BAO)
Beyond the preview
Go deeper on NCT06489925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06489925.